Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

被引：14
|
作者：
Horstmann, K. [1 ,2 ]
Boumendil, A. [1 ]
Finke, J. [3 ]
Finel, H. [1 ]
Kanfer, E. [4 ]
Milone, G. [5 ]
Russell, N. [6 ]
Bacigalupo, A. [7 ]
Chalandon, Y. [8 ,9 ]
Diez-Martin, J. L. [10 ]
Ifrah, N. [11 ]
Jurado Chacon, M. [2 ,12 ]
Dreger, P. [1 ,2 ]
机构：
[1] EBMT Lymphoma Working Party, Paris, France
[2] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany
[3] Univ Freiburg, Dept Med 1, D-79106 Freiburg, Germany
[4] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, London, England
[5] Azienda Osped Policlin Vittorio Emanuele, Programma Trapianto Emopoiet, Catania, Italy
[6] Univ Nottingham Hosp, Ctr Clin Hematol, Nottingham NG7 2UH, England
[7] IRCCS San Martino, Div Hematol & Bone Marrow Transplantat, Genoa, Italy
[8] Univ Hosp Geneva, Div Hematol, Dept Med Specialties, Geneva, Switzerland
[9] Univ Geneva, Fac Med, Geneva, Switzerland
[10] HGU Gregorio Maranon, Dept Hematol & Hemotherapy, Madrid, Spain
[11] CHRU, Serv Malad Sang, Angers, France
[12] Hosp Univ Virgen Ias Nieves, Granada, Spain
来源：
BONE MARROW TRANSPLANTATION | 2015年 / 50卷 / 06期
关键词：
STEM-CELL TRANSPLANTATION; EUROPEAN GROUP; MARROW-TRANSPLANTATION; SOCIETE-FRANCAISE; ACUTE-LEUKEMIA; RISK; STRATEGY; BLOOD; INFUSIONS; SURVIVAL;
D O I：
10.1038/bmt.2015.12
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients >= 18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.
引用
收藏
页码：790 / 794
页数：5
相关论文
共 50 条
  • [1] Management of relapse after allo-SCT for AML and the role of second transplantation
    Savani, B. N.
    Mielke, S.
    Reddy, N.
    Goodman, S.
    Jagasia, M.
    Rezvani, K.
    BONE MARROW TRANSPLANTATION, 2009, 44 (12) : 769 - 777
  • [2] Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT
    Gutierrez-Garcia, G.
    Martinez, C.
    Boumendil, A.
    Finel, H.
    Malladi, R.
    Afanasyev, B.
    Tsoulkani, A.
    Wilson, K. M. O.
    Bloor, A.
    Nikoloudis, M.
    Richardson, D.
    Lopez-Corral, L.
    Castagna, L.
    Cornelissen, J.
    Giltat, A.
    Collin, M.
    Fanin, R.
    Bonifazi, F.
    Robinson, S.
    Montoto, S.
    Peggs, K. S.
    Sureda, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 1018 - 1030
  • [3] Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT
    Martinez, Carmen
    Boumendil, Ariane
    Romejko-Jarosinska, Joanna
    Anagnostopoulos, Achilles
    Faber, Edgar
    Poire, Xavier
    Yakoub-Agha, Ibrahim
    Akhtar, Saad
    Gurman, Gunhan
    Pavone, Vincenzo
    Halaburda, Kazimierz
    Sousa, Aida Botelho
    Ghesquieres, Herve
    Finel, Herve
    Khvedelidze, Irma
    Montoto, Silvia
    Sureda, Anna
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2915 - 2922
  • [4] Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party
    Huebl, Kai
    Re, Alessandro
    Boumendil, Ariane
    Finel, Herve
    Hentrich, Marcus
    Robinson, Stephen
    Wyen, Christoph
    Michieli, Mariagrazia
    Kanfer, Edward
    Diez-Martin, Jose Luis
    Balsalobre, Pascual
    Vincent, Laure
    Schroyens, Wilfried
    Ribera Santasusana, Josep Maria
    Kroeger, Nicolaus
    Schiel, Xaver
    Cwynarski, Kate
    Esquirol, Albert
    Sousa, Aida Botelho
    Cattaneo, Chiara
    Montoto, Silvia
    Dreger, Peter
    BONE MARROW TRANSPLANTATION, 2019, 54 (10) : 1625 - 1631
  • [5] Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Follicular Lymphoma: A Combined Analysis on Behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR
    Sureda, Anna
    Zhang, Mei-Jie
    Dreger, Peter
    Carreras, Jeanette
    Fenske, Timothy
    Finel, Herve
    Schouten, Harry
    Montoto, Silvia
    Robinson, Stephen
    Smith, Sonali M.
    Boumedil, Ariane
    Hamadani, Mehdi
    Pasquini, Marcelo C.
    CANCER, 2018, 124 (08) : 1733 - 1742
  • [6] Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party
    Bazarbachi, Ali
    Boumendil, Ariane
    Finel, Herve
    Mohty, Mohamad
    Castagna, Luca
    Blaise, Didier
    Peggs, Karl S.
    Afanasyev, Boris
    Diez-Martin, J. L.
    Corradini, Paolo
    Michonneau, David
    Robinson, Stephen
    Gutierrez Garcia, Gonzalo
    Bonifazi, Francesca
    Yakoub-Agha, Ibrahim
    Gulbas, Zafer
    Bloor, Adrian
    Delage, Jeremy
    Esquirol, Albert
    Malladi, Ram
    Scheid, Christof
    El-Cheikh, Jean
    Ghesquieres, Herve
    Montoto, Silvia
    Dreger, Peter
    Sureda, Anna
    CANCER, 2019, 125 (01) : 90 - 98
  • [7] Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
    Peggs, Karl S.
    BLOOD ADVANCES, 2018, 2 (07) : 817 - 820
  • [8] Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party
    Bazarbachi, Ali
    Boumendil, Ariane
    Finel, Herve
    Mohty, Mohamad
    Castagna, Luca
    Peggs, Karl S.
    Blaise, Didier
    Afanasyev, Boris
    Diez-Martin, Jose L.
    Sierra, Jorge
    Bloor, Adrian
    Martinez, Carmen
    Robinson, Stephen
    Malladi, Ram
    El-Cheikh, Jean
    Corradini, Paolo
    Montoto, Silvia
    Dreger, Peter
    Sureda, Anna
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (01) : 86 - 96
  • [9] Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party
    Robinson, Stephen P.
    Boumendil, Ariane
    Finel, Herve
    Peggs, Karl S.
    Chevallier, Patrice
    Sierra, Jorge
    Finke, Juergen
    Poire, Xavier
    Maillard, Natacha
    Milpied, Noel
    Yakoub-Agha, Ibrahim
    Koh, Mickey
    Kroeger, Nicolaus
    Nagler, Arnon
    Koc, Yener
    Dietrich, Sascha
    Montoto, Silvia
    Dreger, Peter
    BONE MARROW TRANSPLANTATION, 2018, 53 (05) : 617 - 624
  • [10] Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT
    Castagna, L.
    Boubdallah, R.
    Furst, S.
    Coso, D.
    El Cheikh, J.
    Faucher, C.
    Crocchiolo, R.
    Granata, A.
    Chabannon, C.
    Lemarie, C.
    Calmels, B.
    Boher, J. M.
    Mothy, M.
    Blaise, D.
    BONE MARROW TRANSPLANTATION, 2013, 48 (06) : 794 - 798
12345